As a measles outbreak linked to two Disney parks in California continues to spread, a backlash against parents who refuse or delay vaccination for their children has risen to a fever pitch.
Some areas are starting to see a decline in infections, official says
Teen developed blood disorder after using Aczone for a week
Just because your partner likes to see you in sexy high heels doesn’t mean he has a fetish. Fetishes can be part of a healthy sex life, but they can also be the signs of a sexual disorder, experts tell WebMD.
Cluster of Colorado cases may be tied to 2014 outbreak of enterovirus D68, experts say
By Toni Clarke and Sharon Begley WASHINGTON (Reuters) - The United States has proposed analyzing genetic information from more than 1 million American volunteers as part of a new initiative to understand human disease and develop medicines targeted to an individual's genetic make-up. At the heart of the initiative, to be announced on Friday by President Barack Obama, is the creation of a pool of people - healthy and ill, men and women, old and young - who would be studied to learn how genetic variants affect health and disease. The near-term goal is to create more and better treatments for cancer, Dr. Francis Collins, director of the National Institutes of Health (NIH), told reporters on a conference call on Thursday.
France, the European Union's biggest agricultural producer, has delayed a target to halve pesticide use to 2025 from 2018 after plans to curb their deployment failed, the farm minister said on Friday. France had set a voluntary target of halving pesticide use in the decade to 2018 but it has in fact risen, partly due to adverse weather conditions. Like the EU as a whole, France has sought to become less dependent on pesticides, which are blamed for posing health and environmental risks. The French government has pushed back to 2025 the timeline for halving pesticide use and added an intermediate target of a 25 percent fall by 2020, Agriculture Minister Stephane Le Foll said in an interview in daily newspaper Liberation.
Barring a last-minute breakthrough, drugs firm Sanofi's Chairman Serge Weinberg may have to acknowledge in his results presentation next week that the hunt for a new chief executive is not going well. The manner of Chris Viehbacher's shock dismissal three months ago, and the surprisingly small pay-off he won last week, have cast a long shadow over the process. Paris-schooled Olivier Bohuon, chief executive of British medical devices maker Smith & Nephew, told staff in November he had no plans to leave, and in the same month, former Wyeth boss Bernard Poussot joined the board of Sanofi's rival Roche. Weinberg, who will be 64 on Feb. 10 and does not have a pharmaceuticals background besides his five years on the board, is running Sanofi himself while board member Jean-Rene Fourtou conducts a search -- one which began well before Viehbacher was fired.